Morgan Stanley
BLTE

Morgan Stanley’s Belite Bio BLTE Stock Holding History

Morgan Stanley’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.1M Buy
201,409
+173,396
+619% +$29.2M ﹤0.01% 2526
2025
Q4 		$4.48M Buy
28,013
+22,783
+436% +$2.7M ﹤0.01% 4258
2025
Q3 		$387K Buy
5,230
+4,723
+932% +$310K ﹤0.01% 5617
2025
Q2 		$29.3K Buy
507
+191
+60% +$11.7K ﹤0.01% 6520
2025
Q1 		$20.9K Sell
316
-10,302
-97% -$621K ﹤0.01% 6559
2024
Q4 		$670K Buy
10,618
+9,956
+1,504% +$656K ﹤0.01% 5296
2024
Q3 		$31K Sell
662
-382
-37% -$18.5K ﹤0.01% 6354
2024
Q2 		$47.7K Sell
1,044
-5,046
-83% -$218K ﹤0.01% 6191
2024
Q1 		$234K Sell
6,090
-38,752
-86% -$1.73M ﹤0.01% 5682
2023
Q4 		$2.05M Buy
44,842
+44,404
+10,138% +$1.71M ﹤0.01% 4910
2023
Q3 		$13.9K Hold
438
– – ﹤0.01% 6601
2023
Q2 		$6.26K Sell
438
-600
-58% -$13.6K ﹤0.01% 6933
2023
Q1 		$31K Sell
1,038
-962
-48% -$29.2K ﹤0.01% 6460
2022
Q4 		$60.3K Sell
2,000
-16,308
-89% -$481K ﹤0.01% 6210
2022
Q3 		$615K Buy
+18,308
New +$633K ﹤0.01% 5162

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley's BLTE Position: Q1 2026 in Review

Morgan Stanley increased its Belite Bio (BLTE) stake by 619% in Q1 2026, buying an estimated $29.2M and bringing the position to 201,409 shares worth $32.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

Morgan Stanley first reported a position in BLTE in Q3 2022 and has held it in 15 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Morgan Stanley held 201,409 shares of Belite Bio worth $32.1M as of Q1 2026.
  • Morgan Stanley bought 173,396 Belite Bio shares in Q1 2026, an estimated $29.2M.
  • Belite Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2526 holding.
  • Morgan Stanley first reported a position in Belite Bio in Q3 2022 and has held it in 15 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.